- Home
- AGEN vs PRTS Comparison
AGEN vs PRTS Comparison
Compare AGEN & PRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | PRTS |
|---|---|---|
| Founded | 1994 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto & Home Supply Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.8M | 29.1M |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AGEN | PRTS |
|---|---|---|
| Price | $3.83 | $0.41 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.50 | $0.70 |
| AVG Volume (30 Days) | 450.4K | ★ 783.2K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $106,829,000.00 | ★ $560,632,000.00 |
| Revenue This Year | $67.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $0.41 |
| 52 Week High | $7.34 | $1.42 |
Technical Indicators
Market Signals| Indicator | AGEN | PRTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 34.07 |
| Support Level | $3.82 | $0.41 |
| Resistance Level | $4.12 | $0.45 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 0.58 | 4.41 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About PRTS CarParts.com Inc.
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.